Openbookopenbook
Equity
Eagle Pharmaceuticals Inc(EGRX)
USD --+0.00%
Reward64Moderate
Risk38Moderate
📊75%Data
Thin 5% profit margin · Revenue down 13% YoY
EGRX
+0.0 · +0.00%
USD · NASDAQ
Eagle Pharmaceuticals Inc | Healthcare
Deep Value
Market Cap:3.29M
ℹ️
Reward Rating
64
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
38
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on EGRX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $17.00.

What is Eagle Pharmaceuticals Inc?

, a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

EGRX · Verdict

Solid reward · moderate risk

EGRX scores well on valuation and cash flow with no major weaknesses flagged in the model.

Based on 88% data coverage

EGRX · Verdict

What’s working & what to watch

Strengths 4

  • Valuation93/100

    P/E 11.3× · PEG 0.91

  • Cash flow76/100

    10% free-cash-flow margin

  • Profitability74/100

    11% net margin · 5% ROE

  • Balance sheet71/100

    Interest covered 16.2×

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Eagle Pharmaceuticals Inc?

, a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.29M, and a P/E ratio of 5.0x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (64)

The scoring profile indicates moderate reward potential, with valuation and profitability as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap3.29M
P/E Ratio5
Dividend YieldN/A
52 Week High3.87
52 Week Low0.1
Last AnnualDecember
IPO Date2/12/2014
IncorporatedUSA
Shares Outstanding13M
No. of Employees134
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNASDAQ
Beta0.946
CurrencyUSD
Websitewww.eagleus.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.